DORA-22 is a dual orexin receptor antagonist, improves mild stress-induced insomnia with minimal effect on memory

DORA-22, a dual orexin receptor antagonist, improves mild stress-induced insomnia with minimal effect on memory.DORA-22 treatment improved the insomnia-related sleep disruption-wake was attenuated and NREM sleep was normalized.?REM sleep amounts were enhanced compared with vehicle treatment for one dose (30 mg/kg).?In the first hour of insomnia model exposure, DORA-22 promoted the number and average duration of NREM sleep spindles, which have been previously proposed to play a role in memory consolidation (all doses).?Water maze measures revealed probe trial performance improvement for select doses of DORA-22, including increased time spent in the platform quadrant (10 and 30 mg/kg) and time spent in platform location and number of platform crossings (10 mg/kg only).?In conclusion, DORA-22 treatment improved insomnia-related sleep disruption and memory consolidation deficits[1].

Animals were first trained to remember the location of a hidden platform (acquisition) in the Morris Water Maze and then administered DORA-22 (10, 30, or 100 mg/kg doses) or vehicle control.?Animals were then subjected to a rodent insomnia model involving two exposures to dirty cages over a 6-hr time period (at time points 0 and 3 hr), followed immediately by a probe trial in which memory of the water maze platform location was evaluated[1].